(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Vote in favor of Your #1 BWM Vehicles - 2Hamas set to elect new terror leader with Hayya, Mashaal in pole position
- 3Which Instax Camera Would it be a good idea for you to Purchase?
- 4Vaccine exemptions for religious or personal beliefs are rising across the U.S.
- 5Flourishing as a Charitable Pioneer: Individual Encounters in Generosity
- Iran war pushes Germany's deficit to 4.2% as growth outlook is cut by 50%
- Nature's Treats: 10 Organic products That Lift Prosperity
- The Iconic, Instantly Recognizable Plastic Chair That's Known All Around The World
- FBI arrests Brian Cole Jr. in Jan. 6 pipe bomb investigation, ending 5-year hunt
- Blood pressure drug recalled for possible cross-contamination
- NASA's Voyager 1 set to achieve historic distance from Earth
- How Trump's marijuana executive order could change medical research landscape
- Vote in favor of your #1 Sort of Convenience for a Family
- Uncover the Manageable Fish Practices: Sea agreeable Feasting
